Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 1998

View Archived Issues

Peptech: Annual Report 1997

Clinical syndromes associated with zafirlukast therapy in patients with asthma

Company Profile: Dura

Onyx: Q4 and year-end 1997 highlights

Cambridge NeuroScience: Q4 and year-end 1997 highlights

Organizational changes underway at AHP

First approval for RPR's new combination patch

CLEAR indications of Abelcet efficacy

Sibia Neurosciences: Q4 and year-end 1997 highlights

PLC Systems: Q4 and year-end 1997 highlights

New ACAT-inhibitory malondiamido derivatives from Sanwa

Dual angiotensin II/alpha1-adrenoceptor blockers described by Kyorin

Testosterone 5alpha-reductase inhibitors disclosed by Sumitomo Metal

Janssen describes a new cell migration inhibitor

New antimigraine candidates described by Allelix

Peptech reports novel antiinfective peptides

Nitrullin evaluated in phase II for melanoma

New antimitotic agent described by Czech investigators

Degussa-Huls merger underway

Chiroscience creates Rapigene subsidiary

Boston Life Sciences licenses BCLx-gamma gene from Harvard

PowderJect and Glaxo Wellcome enter DNA vaccine collaboration

Troponin I closer to entering clinical trials

Advanced Magnetics in-licenses contrast agent from Andaris

UT-15 will move to phase III for pulmonary hypertension

First Rx for HIT type II approved in U.S.

Cipro HC approved for otitis

New formulation of methioninase looks promising for clinical testing

PGG-glucan displays potent protective effects in guinea pig model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...